Conolidine’s analgesic outcomes stem from its interaction with non-opioid pain pathways. Compared with opioids, which bind to µ-opioid receptors within the central nervous process, conolidine modulates alternate molecular targets. A Science Advancements review discovered that conolidine interacts Using the atypical chemokine receptor ACKR3/CXCR7, which regulates opioid peptide availab... https://davidc008zrv9.smblogsites.com/profile